logo

Tag : licensing

Attorneys vs. Business

Value your attorneys advice, but remember the rules of business when making life science deals.Last week my father, who is a real estate broker and an attorney, was telling me about a real estate deal that he was working on. The buyer and seller had initially been in relatively good agreement but the seller’s attorney continuously advised his client to take an increasingly risk-averse position, thereby making the deal more one-sided and threatening it entirely. This reminded me of another conversation that some of us on the Life Science Distributors group on LinkedIn were discussing: how many large manufacturers (and this applies to large distributors as well) often have heavily one-sided distribution agreements that minimize their risk but fail to consider their partners. It was mentioned that such agreements are often drafted by attorneys.

My father made a very astute statement: “Attorneys seem to have forgotten the realities of business in favor of minimizing risk for their clients”. While there are exceptions, and there are also certain situations in which extreme caution may be justified, the idea of the statement is too-often true. When attorneys get involved they often do not have a complete understanding of the business environment and / or the situation relevant to a particular business deal. This applies across almost all industries and markets, and life science research tools are no exception.

Whether the issue at hand is distribution agreements, licencing deals, partnerships, service agreements, or just about any other contractual and / or negotiated agreement, remember to take your lawyers advice seriously, but don’t let them overrule the basic rules of business. Almost any deal requires a little bit of give and take, and focusing too strictly on risk reduction can ultimately scuttle what would otherwise be a highly lucrative deal. When your life science company deals with its attorneys, value their advice, but don’t forget the rules of business in doing so.

"Looking for an expert life science deal-maker or business developer to help grow your business? Contact us to confidentially discuss your needs and how we can help you achieve your goals."

Supreme Court: Bayh-Dole Act

Maximizing distributor performance allows bioscience companies to efficiently grow revenues.Last week, the Supreme Court ruled in the case of Stanford vs. Roche Molecular Systems, which has implications for academic inventors who receive federal funding for their research. Stanford was suing Roche Molecular Systems, claiming saying RMS did not have the rights to a patent which described a test to quantify the HIV load in a patient’s blood, which is now commonly used. RMS had bought the rights from Cetus Corporation, a private company at which a Stanford fellow, Dr. Mark Holodniy, had been assigned by Stanford to conduct research and at which Dr. Holodniy had invented the HIV load test in question.

In their prosecution, Stanford used the Bayh-Dole Act to argue that the intellectual property was rightfully theirs. For those who may be unfamiliar with the act, the Bayh-Dole Act (also known as the Patent and Trademark Law Amendments Act) granted universities, non-profit institutions, and small businesses within the United States the rights to intellectual property resulting from U.S. government-funded research. In defense, Roche Molecular Systems argued a simple point of wording. Dr. Holodniy’s contract with Stanford stated that “I agree to assign” intellectual property resulting from his fellowship at Stanford to the university, while his contract from Cetus stated that “I will assign and do hereby assign” such IP.

Despite that the Bayh-Dole Act states (albeit extremely verbosely) that rights to government-funded inventions lie first with the funded firm, then with the United States government, and lastly with the individual inventor, the Supreme Court ruled 7-2 that Cetus indeed rightfully owned the IP that they sold to Roche Molecular Systems. Chief Justice John Roberts wrote for the majority that the Bayh-Dole act does not automatically strip employees of the rights to intellectual property and because of the weak wording of Stanford’s contract (saying “will assign” instead of “do assign”) that Stanford never actually held the rights to Dr. Holodniy’s invention in the first place. You can read the full case syllabus and opinions in this pdf on supremecourt.gov.

What is of significance here is that Justice Roberts affirmed in the court opinion “the general rule that rights in an invention belong to the inventor”. This would indicate that companies, universities, and other institutions may need to have a very clear and explicit agreement that the individuals turn over their intellectual property to their institutions or else the individual may actually retain the rights, especially when the work is federally funded.

Disclaimer

BioBM Consulting is not a law firm and does not provide legal advice. If you have any questions regarding the law, please refer them to an appropriate licensed legal professional. For questions related to patent law, especially as it pertains to life science or biomedical patents, we highly recommend Gordin IP.

"Are you a life science inventor and have a great idea that you would like to commercialize? BioBM may be able to help you. Our inventor services allow scientist-inventors to inexpensively commercialize and profit from their inventions. We can guide you through all the necessary steps to sell, licence, or build a company around your intellectual property. Feel free to contact us and confidentially discuss your idea and desires."

BioBM Launches Inventor Services

BioBM Consulting is pleased to announce the launch of its new “Inventor Services” division, offering commercialization services to life science inventors and others who wish to commercialize intellectual property with a life science research focus. Celebrating the latest in BioBM’s expanding and innovative service offerings, BioBM Principal Consultant Carlton Hoyt gave the following statement:

Statement from Principal Consultant Carlton Hoyt

BioBM recognizes the massive creative capacity of life science researchers and simultaneously realizes that inventors in life science laboratories may lack access to key business and marketing experience necessary for effective and profitable commercialization of such inventions. With BioBM’s unique positioning, we recognize the value we have to offer life science inventors and can help them commercialize novel biotechnology innovations in a variety of ways. We strive to help life science inventors meet their commercial goals while expediting the development and marketing of advancements in life science tools and processes that will forward the sciences and, ultimately, human health. BioBM looks forward to fruitful collaborations with inventors from all areas of the life sciences.


The Inventor Services division of BioBM is already taking inquiries. For more information on how BioBM Consulting works with inventors, click here. For more information on the portfolio of services offered to inventors, click here.